Vaxcyte, Inc. (FRA:5VA)

Germany flag Germany · Delayed Price · Currency is EUR
39.40
-1.00 (-2.48%)
Last updated: Dec 5, 2025, 11:41 AM CET
-54.19%
Market Cap 5.23B
Revenue (ttm) n/a
Net Income (ttm) -560.13M
Shares Out n/a
EPS (ttm) -4.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 35
Open 40.00
Previous Close 40.40
Day's Range 39.40 - 40.00
52-Week Range 24.60 - 89.50
Beta n/a
RSI 51.40
Earnings Date Feb 25, 2026

About Vaxcyte

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2013
Employees 414
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5VA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.